MyoKardia (MYOK) Earning Somewhat Positive Media Coverage, Report Shows
Media headlines about MyoKardia (NASDAQ:MYOK) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MyoKardia earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.2444125471719 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- MyoKardia, Inc. (MYOK) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference (finance.yahoo.com)
- MyoKardia, Inc. (NASDAQ:MYOK) Insider Jake Bauer Sells 15,000 Shares (americanbankingnews.com)
- MyoKardia, Inc. (NASDAQ:MYOK) Insider Sells $450,000.00 in Stock (americanbankingnews.com)
- MyoKardia transforms inherited heart disease symptoms in mid-stage trial (joshnaijablog.com)
MyoKardia (NASDAQ MYOK) opened at 36.70 on Friday. MyoKardia has a 12-month low of $10.55 and a 12-month high of $37.88. The firm’s market cap is $1.16 billion. The company has a 50-day moving average price of $17.34 and a 200-day moving average price of $14.04.
MyoKardia (NASDAQ:MYOK) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.04. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The company’s revenue was up 60.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.37) EPS. On average, analysts predict that MyoKardia will post ($1.64) earnings per share for the current year.
A number of analysts have recently issued reports on MYOK shares. BMO Capital Markets reissued an “outperform” rating and issued a $32.00 price target on shares of MyoKardia in a research report on Wednesday, May 10th. Zacks Investment Research lowered shares of MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet lowered shares of MyoKardia from a “c-” rating to a “d+” rating in a research report on Friday, May 19th. BidaskClub raised shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $48.00 price target (up from $31.00) on shares of MyoKardia in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $37.60.
In other MyoKardia news, insider Jake Bauer sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $28.33, for a total transaction of $424,950.00. Following the transaction, the insider now owns 75,545 shares of the company’s stock, valued at approximately $2,140,189.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anastasios Gianakakos sold 32,988 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $15.00, for a total value of $494,820.00. Following the transaction, the insider now directly owns 541,151 shares in the company, valued at approximately $8,117,265. The disclosure for this sale can be found here. Insiders sold a total of 67,288 shares of company stock worth $1,441,236 in the last 90 days. Company insiders own 46.10% of the company’s stock.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.